Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced ... https://t.co/8xuwx2ECj7
Nel microcitoma, un nuovo farmaco pare diminuire -in maniera statisticamente significativa- la tossicità midollare da chemioterapia. Si chiama: TRILACICLIB https://t.co/wR0h6xN9O8
New article: Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind,… https://t.co/ATprAJa9t5 #lungcancer #on
Myeloprotective Effects of #Trilaciclib Among Patients With #Small_Cell_Lung_Cancer at Increased Risk of #Chemotherapy-Induced #Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies https://t.co/32vyJv3r4